Solos Endoscopy, a healthcare instrument that develops and markets devices for screening, diagnosis, treatment and management of medical conditions, has secured US Trademark for MammoView name, a breast endoscopy system that offers technology for detecting early stage breast cancer.
Solos Endoscopy’s breast endoscopy system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise. The equipment will distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods. It performs related intraductal procedures with direct visualization of tissues. In addition, it complements existing diagnosis and treatment with direct endoscopic observation.
Solos Endoscopy has been granted the US trademark registration 3637510 for the protection of the MammoView name. A registered trademark on the US PTO’s principal register grants a bundle of exclusive rights upon the registered owner, including the right to exclusive use of the mark in relation to the products or services for which it is registered.
The law in most jurisdictions also allows the owner of a registered trademark to prevent unauthorized use of the mark in relation to products or services that are identical or ‘colorfully’ similar to the ‘registered’ products or services, and in certain cases, prevent use in relation to entirely dissimilar products or services.
Bob Segersten, CEO of Solos Endoscopy, said: “Securing the trademark for the MammoView brand is a significant asset to the company. This is not only important to our business domestically, but as we continue or work in achieving the CE Mark, this registration can be used as a basis for obtaining registration in other countries.”